VANCOUVER, British Columbia and WARMINSTER, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:...

Combinations of Arbutus' RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus' Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award VANCOUVER, British Columbia and WARMINSTER, Pa., May 22, 2017...

3 HBV Product Candidates Progressing in Clinical Development Cash Runway to Late 2018 Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an...

VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 at 1:30 PM Pacific...

ARB-1467 Reduces Serum HBsAg in Both HBeAg Negative and HBeAg Positive Patients Results of Biweekly Dosing from Cohort 4 Expected in 3Q17 Additional Study Starting in 2H17 to Evaluate Longer Term Dosing with Immune Modulatory Agents VANCOUVER, British Columbia and WARMINSTER, Pa., April 22, 2017...

Acuitas Prevented from Any Further LNP Licensing to Moderna or Other Parties

VANCOUVER, B.C. and DOYLESTOWN, Pa., March 23, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors and Audit Committee...

3 HBV Product Candidates in the Clinic in 1Q17 Cash Runway into Late 2018 Company to Host a Corporate Update Conference Call Today at 2:00 PM ET VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading...

Agreement Calls for Upfront and Potential Milestone Payments of Over $80 Million Plus Royalties

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 06, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in two upcoming investor conferences....